On August 28, 2023, the U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Hodgkin’s lymphoma (HL) has had an exciting and…
Imetelstat in low-risk MDS for transfusion independence By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center …
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with…
By Dr. Chepsy Philip Believer's Church Medical College Hospital Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the…
By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the…
The Binaytara Foundation organized three in-person oncology conferences in October 2021. The 2021 Updates in Hematologic Malignancies and the 2021…